Outcomes in patients with chronic Hep C treated with different anti-viral regimens
The latest issue of the American Journal of Gastroenterology performs an in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens.
Interferon- and ribavirin-containing regimens negatively impact patients’ experience.
Dr Zobair Younossi and colleagues from Virginia, USA quantified the impact of different anti-viral regimens for hepatitis C on patients’ work productivity, fatigue, and other patient-reported outcomes.
The patient-reported outcome data from multicenter multinational phase 3 clinical trials of sofosbuvir with and without interferon or ribavirin were retrospectively used.
Treatment regimens were classified as interferon+ribavirin-containing, interferon-free ribavirin-containing, and interferon-free ribavirin-free.
The team administered 4 patient-reported outcome instruments to subjects at baseline, during, and up to 24 weeks after treatment.
Interferon was associated with up to −26% worsening of the patient-reported outcome scores
American Journal of Gastroenterology
The researchers included 3,425 subjects with chronic hepatitis C infection with patient-reported outcome data.
The team found that patients were 63% male, 62% treatment naive, 18% with cirrhosis, and 73% with HCV genotype 1.
Of the study participants, 546 received interferon+ribavirin+sofosbuvir, 1,721 received sofosbuvir+ribavirin, and 1,158 received interferon- and ribavirin-free ledipasvir+sofosbuvir.
At baseline, there were no difference in patient-reported outcomes between treatment groups.
During treatment, the decrements in patient-reported outcomes were up to −24% for the interferon+ribavirin group, up to −7% in the sofosbuvir+ribavirin group, whereas there was an improvement of up to +12% in the interferon-free ribavirin-free group.
The researchers found that use of interferon was independently associated with up to −26% worsening of the patient-reported outcome scores during treatment and the use of ribavirin with up to −9% worsening.
The team noted that after 12 weeks post-treatment, in patients with sustained virologic response-12, improvements were observed regardless of the regimen, and these improvements continued to increase by week 24 of follow-up.
Dr Younossi's team concludes, "The use of interferon- and ribavirin-free regimens for HCV is associated with better patients’ experience, and work productivity during treatment."
Am J Gastroenterol 2016; 111:808–816
14 June 2016
The latest issue of the American Journal of Gastroenterology performs an in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens.
Interferon- and ribavirin-containing regimens negatively impact patients’ experience.
Dr Zobair Younossi and colleagues from Virginia, USA quantified the impact of different anti-viral regimens for hepatitis C on patients’ work productivity, fatigue, and other patient-reported outcomes.
The patient-reported outcome data from multicenter multinational phase 3 clinical trials of sofosbuvir with and without interferon or ribavirin were retrospectively used.
Treatment regimens were classified as interferon+ribavirin-containing, interferon-free ribavirin-containing, and interferon-free ribavirin-free.
The team administered 4 patient-reported outcome instruments to subjects at baseline, during, and up to 24 weeks after treatment.
Interferon was associated with up to −26% worsening of the patient-reported outcome scores
American Journal of Gastroenterology
The researchers included 3,425 subjects with chronic hepatitis C infection with patient-reported outcome data.
The team found that patients were 63% male, 62% treatment naive, 18% with cirrhosis, and 73% with HCV genotype 1.
Of the study participants, 546 received interferon+ribavirin+sofosbuvir, 1,721 received sofosbuvir+ribavirin, and 1,158 received interferon- and ribavirin-free ledipasvir+sofosbuvir.
At baseline, there were no difference in patient-reported outcomes between treatment groups.
During treatment, the decrements in patient-reported outcomes were up to −24% for the interferon+ribavirin group, up to −7% in the sofosbuvir+ribavirin group, whereas there was an improvement of up to +12% in the interferon-free ribavirin-free group.
The researchers found that use of interferon was independently associated with up to −26% worsening of the patient-reported outcome scores during treatment and the use of ribavirin with up to −9% worsening.
The team noted that after 12 weeks post-treatment, in patients with sustained virologic response-12, improvements were observed regardless of the regimen, and these improvements continued to increase by week 24 of follow-up.
Dr Younossi's team concludes, "The use of interferon- and ribavirin-free regimens for HCV is associated with better patients’ experience, and work productivity during treatment."
Am J Gastroenterol 2016; 111:808–816
14 June 2016
No comments:
Post a Comment